# US 2021/0262035 A1 · Non-invasive detection of fetal genetic traits

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0262035 A1
- Document ID: US20210262035A1
- Status: Published application
- Kind: A1
- Application number: 17/317,240
- Filed: 2021-05-11
- Published: 2021-08-26
- Earliest claimed: 2003-10-16
- Assignees: Sequenom, Inc.
- Applicants: Sequenom, Inc.
- Inventors: Sinuhe HAHN; Wolfgang HOLZGREVE; Bernhard ZIMMERMANN; Ying LI
- Web page: https://patentgrep.com/patent/US20210262035A1

## CPC

- C12Q 1/6883: for diseases caused by alterations of genetic material
- C12Q 1/6806: Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay (C12Q1/6804 takes precedence)
- C12Q 2600/156: Polymorphic or mutational markers
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

Blood plasma of pregnant women contains fetal and (generally >90%) maternal circulatory extracellular DNA. Most of said fetal DNA contains 500 base pairs, said maternal DNA having a greater size. Separation of circulatory extracellular DNA of <500 base pairs results in separation of fetal from maternal DNA. A fraction of a blood plasma or serum sample of a pregnant woman containing, due to size separation (e.g. by chromatography, density gradient centrifugation or nanotechnological methods), extracellular DNA substantially comprising 500 base pairs is useful for non-invasive detection of fetal genetic traits (including the fetal RhD gene in pregnancies at risk for HDN; fetal Y chromosome-specific sequences in pregnancies at risk for X chromosome-linked disorders; chromosomal aberrations; hereditary Mendelian genetic disorders and corresponding genetic markers; and traits decisive for paternity determination) by e.g. PCR, ligand chain reaction or probe hybridization techniques, or nucleic acid arrays.

## Claims

### Claim 1

A composition, produced by a process comprising:
(a) extracting DNA comprising maternal and fetal DNA fragments from a substantially cell-free sample of blood plasma or blood serum of a pregnant human female;
(b) producing a composition of the DNA extracted in (a) by:
(i) size discrimination of extracellular circulatory fetal and maternal DNA fragments, and
(ii) selectively removing the DNA fragments greater than approximately 300 base pairs,
wherein the DNA composition after (b) comprises extracellular circulatory fetal and maternal DNA fragments of approximately 300 base pairs and less and a plurality of genetic loci of the extracellular circulatory fetal and maternal DNA fragments.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the DNA fragments are in solution.

### Claim 3 (depends on 1)

The composition of claim 1, wherein the composition facilitates non-invasive detection of fetal genetic traits.

### Claim 4 (depends on 3)

The composition of claim 3, wherein the fetal genetic trait is involved in a chromosomal aberration.

### Claim 5 (depends on 4)

The composition of claim 4, wherein the chromosomal aberration is a chromosome aneuploidy.

### Claim 6 (depends on 5)

The composition of claim 5, wherein the chromosome aneuploidy is associated with Down's syndrome.

### Claim 7 (depends on 1)

The composition of claim 1, wherein the composition is in a container.

### Claim 8 (depends on 1)

The composition of claim 1, in association with a solid phase, wherein the solid phase is not a gel.

### Claim 9 (depends on 1)

The composition of claim 1, wherein (b) comprises chromatography.

### Claim 10 (depends on 9)

The composition of claim 9, wherein the chromatography comprises high performance liquid chromatography.

### Claim 11 (depends on 1)

The composition of claim 1, wherein (b) comprises electrophoresis.

### Claim 12 (depends on 11)

The composition of claim 11, wherein the electrophoresis comprises capillary electrophoresis.

### Claim 13 (depends on 1)

The composition of claim 1, wherein (b) comprises centrifugation.

### Claim 14 (depends on 13)

The composition of claim 13, wherein the centrifugation includes density gradient centrifugation.

### Claim 15 (depends on 1)

The composition of claim 1, wherein (b) comprises a nanotechnological means.

### Claim 16 (depends on 3)

The composition of claim 3, wherein non-invasive detection of fetal genetic traits comprises analyzing the composition by using nucleic acid arrays.

### Claim 17 (depends on 3)

The composition of claim 3, wherein non-invasive detection of fetal genetic traits comprises analyzing the composition by amplifying DNA.

### Claim 18 (depends on 17)

The composition of claim 17, wherein the amplifying comprises use of a polymerase chain reaction.

### Claim 19 (depends on 17)

The composition of claim 17, wherein the amplifying comprises use of a ligase chain reaction.
